Canada recommends Leqembi reimbursement
Analysis based on 6 articles · First reported Sep 01, 2026 · Last updated Sep 01, 2026
The positive reimbursement recommendation is expected to boost sales of Leqembi in Canada, benefiting BioArctic through royalties and Eisai through direct sales. This regulatory milestone may also strengthen investor confidence in the drug's commercial potential, positively impacting the stock prices of BioArctic and Eisai.
On September 1, 2026, Canada — Canada s Drug Agency (CDA-AMC) issued a final positive recommendation supporting public reimbursement of Leqembi (lecanemab) for eligible patients in Canada with mild cognitive impairment or mild dementia due to Alzheimer's disease. The recommendation follows a reconsideration and is a key step toward broadening access to the drug in Canada. Next steps include negotiations through the Pan-Canadian Pharmaceutical Alliance and reimbursement decisions by provincial and territorial drug plans. Leqembi, developed by BioArctic and Eisai, is already approved in 53 countries and under review in 6. The announcement is significant for BioArctic, which is entitled to royalties on global sales, and for Eisai, which leads commercialization. The decision could expand the patient population in Canada, where over 770,000 people were living with dementia in 2025, a number projected to rise to 1.7 million by 2050.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard